Characterization of the novel positive allosteric modulator of the metabotropic glutamate receptor 4 ADX88178 in rodent models of neuropsychiatric disorders

Mikhail Kalinichev, Emmanuel Le Poul, Christelle Boléa, Françoise Girard, Brice Campo, Massimiliano Fonsi, Isabelle Royer-Urios, Susan E. Browne, Jason M. Uslaner, Matthew J. Davis, Jacob Raber, Robert Duvoisin, Simon T. Bate, Ian J. Reynolds, Sonia Poli, Sylvain Celanire

Research output: Contribution to journalArticle

38 Scopus citations

Abstract

There is growing evidence that activation of metabotropic glutamate receptor 4 (mGlu4) leads to anxiolytic- and antipsychotic-like efficacy in rodent models, yet its relevance to depression-like reactivity remains unclear. Here, we present the pharmacological evaluation of ADX88178 [5-methyl-N-(4-methylpyrimidin-2-yl)-4-(1H-pyrazol-4-yl)thiazol-2-amine], a novel potent, selective, and brain-penetrant positive allosteric modulator of the mGlu4 receptor in rodent models of anxiety, obsessive compulsive disorder (OCD), fear, depression, and psychosis. ADX88178 dose-dependently reduced the number of buried marbles in the marble burying test and increased open-arm exploration in the elevated plus maze (EPM) test, indicative of anxiolytic-like efficacy. Target specificity of the effect in the EPM test was confirmed using male and female mGlu4 receptor knockout mice. In mice, ADX88178 reduced the likelihood of conditioned freezing in the acquisition phase of the fear conditioning test, yet had no carryover effect in the expression phase. Also, ADX88178 dose-dependently reduced duration of immobility in the forced swim test, indicative of antidepressant-like efficacy. ADX88178 reduced DOI (2,5-dimethoxy-4-iodoamphetamine)-mediated head twitches (albeit with no dose-dependency), and MK-801 [(5S,10R)-(+)-5-methyl-10,11-dihydro-5H- dibenzo[a,d]cyclohepten-5,10-imine]-induced locomotor hyperactivity in mice, but was inactive in the conditioned avoidance response test in rats. The compound showed good specificity as it had no effect on locomotor activity in mice and rats at efficacious doses. Thus, allosteric activation of mGlu4 receptors can be a promising new therapeutic approach for treatment of anxiety, OCD, fear-related disorders, and psychosis.

Original languageEnglish (US)
Pages (from-to)495-505
Number of pages11
JournalJournal of Pharmacology and Experimental Therapeutics
Volume350
Issue number3
DOIs
StatePublished - Sep 2014

ASJC Scopus subject areas

  • Molecular Medicine
  • Pharmacology

Fingerprint Dive into the research topics of 'Characterization of the novel positive allosteric modulator of the metabotropic glutamate receptor 4 ADX88178 in rodent models of neuropsychiatric disorders'. Together they form a unique fingerprint.

  • Cite this

    Kalinichev, M., Le Poul, E., Boléa, C., Girard, F., Campo, B., Fonsi, M., Royer-Urios, I., Browne, S. E., Uslaner, J. M., Davis, M. J., Raber, J., Duvoisin, R., Bate, S. T., Reynolds, I. J., Poli, S., & Celanire, S. (2014). Characterization of the novel positive allosteric modulator of the metabotropic glutamate receptor 4 ADX88178 in rodent models of neuropsychiatric disorders. Journal of Pharmacology and Experimental Therapeutics, 350(3), 495-505. https://doi.org/10.1124/jpet.114.214437